ORGO · Insider Trading
Organogenesis Holdings Inc. Class A Common Stock
Every open-market purchase and sale reported by ORGO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-24 | Brian Grow | Chief Commercial Officer | M | +958 | +$1.19K |
| 2026-03-11 | Arthur S Leibowitz | Director | Buy | +5,000 | +$13.40K |
| 2026-03-11 | Michael Joseph Driscoll | Director | Buy | +10,000 | +$26.69K |
| 2026-03-03 | Robert Cavorsi | Vice President, Strategy | F | −700 | −$2.25K |
| 2026-03-03 | Antonio S. Montecalvo | Vice President, Health Policy | MIXED | +7,552 | −$14.51K |
| 2026-03-03 | Robert Cavorsi | Vice President, Strategy | MIXED | +10,967 | −$21.07K |
| 2026-03-03 | Gary S. Gillheeney | President and CEO | MIXED | +97,545 | −$350.63K |
| 2026-03-03 | Brian Grow | Chief Commercial Officer | MIXED | +36,931 | −$45.65K |
| 2026-03-03 | Patrick Bilbo | Chief Operating Officer | MIXED | +32,727 | −$62.88K |
| 2026-03-03 | Lori Freedman | Chief Admin. and Legal Officer | MIXED | +28,801 | −$55.34K |
| 2026-03-03 | David Francisco | Chief Financial Officer | MIXED | +29,353 | −$56.40K |
| 2026-02-20 | Michele Ilene Korfin | Director | A | +48,828 | — |
| 2026-02-20 | Patrick Bilbo | Chief Operating Officer | MIXED | +243,337 | −$62.25K |
| 2026-02-20 | Antonio S. Montecalvo | Vice President, Health Policy | MIXED | +48,102 | −$14.37K |
| 2026-02-20 | Garrett Lustig | Director | A | +48,828 | — |
| 2026-02-20 | Jon L Giacomin | Director | A | +48,828 | — |
| 2026-02-20 | Brian Grow | Chief Commercial Officer | MIXED | +270,937 | −$45.19K |
| 2026-02-20 | Michael Joseph Driscoll | Director | A | +48,828 | — |
| 2026-02-20 | Prathyusha Duraibabu | Director | A | +48,828 | — |
| 2026-02-20 | Gilberto Quintero | Director | A | +48,828 | — |
| 2026-02-20 | Gary S. Gillheeney | President and CEO | MIXED | +987,195 | −$347.13K |
| 2026-02-20 | Lori Freedman | Chief Admin. and Legal Officer | MIXED | +231,638 | −$54.79K |
| 2026-02-20 | Robert Cavorsi | Vice President, Strategy | MIXED | +104,608 | −$20.86K |
| 2026-02-20 | Arthur S Leibowitz | Director | A | +48,828 | — |
| 2026-02-20 | David Francisco | Chief Financial Officer | MIXED | +224,373 | −$55.84K |
| 2026-02-18 | Gary S. Gillheeney | President and CEO | F | −271,406 | −$1.01M |
| 2026-02-18 | Brian Grow | Chief Commercial Officer | F | −43,959 | −$163.97K |
| 2026-02-18 | Lori Freedman | Chief Admin. and Legal Officer | F | −54,742 | −$204.19K |
| 2026-02-18 | Patrick Bilbo | Chief Operating Officer | F | −64,414 | −$240.26K |
| 2026-02-18 | David Francisco | Chief Financial Officer | F | −52,448 | −$195.63K |
| 2026-02-18 | Robert Cavorsi | Vice President, Strategy | F | −17,658 | −$65.86K |
| 2026-02-18 | Antonio S. Montecalvo | Vice President, Health Policy | F | −18,619 | −$69.45K |
| 2025-12-18 | Glenn H Nussdorf | Director | Sell | −200,000 | −$1.03M |
| 2025-11-26 | Glenn H Nussdorf | Director | Sell | −300,000 | −$1.59M |
| 2025-11-03 | Glenn H Nussdorf | Director | MIXED | +335,719 | +$1.02M |
| 2025-08-13 | Brian Grow | Chief Commercial Officer | MIXED | +1,887 | −$0 |
| 2025-07-18 | Robert Cavorsi | Vice President, Strategy | F | −360 | −$1.61K |
| 2025-06-06 | Lori Freedman | Chief Admin. and Legal Officer | Buy | +252,264 | +$725.29K |
| 2025-03-12 | Robert Cavorsi | Vice President, Strategy | F | −271 | −$1.40K |
| 2025-03-06 | Michael Joseph Driscoll | Director | Sell | −25,000 | −$127.53K |
| 2025-03-04 | Robert Cavorsi | Vice President, Strategy | F | −667 | −$4.14K |
| 2025-02-21 | Jon L Giacomin | Director | A | +49,575 | — |
| 2025-02-21 | Garrett Lustig | Director | A | +49,575 | — |
| 2025-02-21 | Lori Freedman | Chief Admin. and Legal Officer | A | +162,047 | — |
| 2025-02-21 | Prathyusha Duraibabu | Director | A | +49,575 | — |
| 2025-02-21 | Arthur S Leibowitz | Director | A | +49,575 | — |
| 2025-02-21 | David Francisco | Chief Financial Officer | A | +165,156 | — |
| 2025-02-21 | Michael Joseph Driscoll | Director | A | +49,575 | — |
| 2025-02-21 | Gilberto Quintero | Director | A | +49,575 | — |
| 2025-02-21 | Brian Grow | Chief Commercial Officer | A | +183,067 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| RED Holdings, LLC | 10%+ Owner | 111,033,430 | $143.23M |
| 2016 GN 2016 Organo 10-Year GRAT u/a/d September 30 | 10%+ Owner | 110,533,430 | $142.59M |
| Josette Ades | 10%+ Owner | 102,170,806 | $131.80M |
| Organo Investors LLC | 10%+ Owner | 102,170,806 | $131.80M |
| Albert Erani Family Trust dated 12/29/2012 | 10%+ Owner | 102,170,804 | $131.80M |
| Alan A. Ades | Director | 102,170,804 | $131.80M |
| Dennis Erani 2012 Issue Trust dated 12/20/12 | 10%+ Owner | 54,136,225 | $69.84M |
| Ades 2014 GRAT Alan | 10%+ Owner | 51,085,403 | $65.90M |
| Gary S. Gillheeney | President and CEO | 4,232,087 | $5.46M |
| Glenn H Nussdorf | Director | 2,901,310 | $3.74M |
| Patrick Bilbo | Chief Operating Officer | 1,144,687 | $1.48M |
| Lori Freedman | Chief Admin. and Legal Officer | 1,038,054 | $1.34M |
| Brian Grow | Chief Commercial Officer | 900,682 | $1.16M |
| David Francisco | Chief Financial Officer | 731,312 | $943.39K |
| Arthur S Leibowitz | Director | 291,014 | $375.41K |
| Robert Cavorsi | Vice President, Strategy | 276,224 | $356.33K |
| Prathyusha Duraibabu | Director | 247,047 | $318.69K |
| Jon L Giacomin | Director | 241,026 | $310.92K |
| Michele Ilene Korfin | Director | 239,073 | $308.40K |
| Gilberto Quintero | Director | 239,073 | $308.40K |
| Antonio S. Montecalvo | Vice President, Health Policy | 230,016 | $296.72K |
| Michael Joseph Driscoll | Director | 225,707 | $291.16K |
| Garrett Lustig | Director | 125,742 | $162.21K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ORGO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.